ReviewCancers2014
Positron Emission Tomography (PET) in Oncology.
Review in Cancers, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 157 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
157 citing papers in PubMed, 4 syntheses or guidelines pooled it, 309 citations in OpenAlex.
- Application of immunoPET imaging to enhance head and neck squamous cell carcinoma clinical management.Frontiers in oncology · 2025Pooled it
- Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.The Cochrane database of systematic reviews · 2021Pooled it
- Pooled it
- Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Diagnostic performance of real-time robotic arm-assistedEuropean journal of nuclear medicine and molecular imaging · 2019Trial
- Intraoperative Molecular Imaging Combined With Positron Emission Tomography Improves Surgical Management of Peripheral Malignant Pulmonary Nodules.Annals of surgery · 2017Trial
- Addressing unmet needs in nuclear medicine: Italian experience with PET/CT features and structured reporting in oncology.La Radiologia medica · 2026Article
- Beyond the Needle: Is Liquid Biopsy the Future of Veterinary Medicine?International journal of molecular sciences · 2026Review
- Graphene Oxide (GO) and Gold Nanoparticles (AuNP) Facilitated Electrochemical Biosensing for Lung Cancer Diagnosis.Diagnostics (Basel, Switzerland) · 2026Review
- Comparative efficacy and workflow efficiency of integrated PET/MRI versus sequential PET/CT and MRI in gynecologic cancer staging: a prospective single-center study.Abdominal radiology (New York) · 2026Article
- Development of a Prototype AWSM-PET Device for Augmented Whole-Body PET Imaging and Initial Human Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Scanner-integrated reconstruction versus post-processing deep learning for low-countEJNMMI physics · 2026Article
- SpecificTheranostics · 2026Article
- Using multimodal PET+MR data as conditional generative adversarial network inputs improves pseudo-CT and attenuation correction estimates for brain PET/MR.American journal of nuclear medicine and molecular imaging · 2026Article
- Phenotypic stratification of Low-grade Glioma using multimodal MRI via outcome-weighted integrative clustering.BMC neurology · 2025Article
- Quantification ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Clinical validation of a deep learning model for low-count PET image enhancement.European journal of nuclear medicine and molecular imaging · 2025Article
- On the effect of reference and sample volume on magnetic particle imaging quantification.Journal of magnetism and magnetic materials · 2025Article
- Article
- Prognostic value of baseline body composition parameters fromAnnals of hematology · 2025Article
97 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since its introduction in the early nineties as a promising functional imaging technique in the management of neoplastic disorders, FDG-PET, and subsequently FDG-PET/CT, has become a cornerstone in several oncologic procedures such as tumor staging and restaging, treatment efficacy assessment during or after treatment end and radiotherapy planning. Moreover, the continuous technological progress of image generation and the introduction of sophisticated software to use PET scan as a biomarker paved the way to calculate new prognostic markers such as the metabolic tumor volume (MTV) and the total amount of tumor glycolysis (TLG). FDG-PET/CT proved more sensitive than contrast-enhanced CT scan in staging of several type of lymphoma or in detecting widespread tumor dissemination in several solid cancers, such as breast, lung, colon, ovary and head and neck carcinoma. As a consequence the stage of patients was upgraded, with a change of treatment in 10%-15% of them. One of the most evident advantages of FDG-PET was its ability to detect, very early during treatment, significant changes in glucose metabolism or even complete shutoff of the neoplastic cell metabolism as a surrogate of tumor chemosensitivity assessment. This could enable clinicians to detect much earlier the effectiveness of a given antineoplastic treatment, as compared to the traditional radiological detection of tumor shrinkage, which usually takes time and occurs much later.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.